MediWound Ltd. (NASDAQ:MDWD - Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $20.00 and traded as high as $20.74. MediWound shares last traded at $20.47, with a volume of 86,389 shares trading hands.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on MDWD. Wall Street Zen raised shares of MediWound to a "sell" rating in a research report on Friday, March 21st. Oppenheimer began coverage on shares of MediWound in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 price objective for the company. HC Wainwright set a $31.00 price objective on shares of MediWound and gave the company a "buy" rating in a research report on Thursday, May 22nd. Finally, Alliance Global Partners began coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.
Get Our Latest Stock Analysis on MediWound
MediWound Stock Performance
The company has a market cap of $219.88 million, a P/E ratio of -9.72 and a beta of 0.32. The firm's fifty day moving average is $20.14 and its two-hundred day moving average is $18.44.
MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.58. The company had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. During the same quarter in the prior year, the firm posted ($1.05) EPS. On average, equities research analysts expect that MediWound Ltd. will post -2.66 EPS for the current year.
Institutional Trading of MediWound
Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in shares of MediWound by 1,507.1% during the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 1,703 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 1,162 shares in the last quarter. Corebridge Financial Inc. raised its position in shares of MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 999 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of MediWound by 2,255.2% during the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock valued at $98,000 after buying an additional 6,044 shares in the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Stories
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
